Patriot Financial Group Insurance Agency LLC Buys 2,165 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Patriot Financial Group Insurance Agency LLC increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 7.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,586 shares of the company’s stock after purchasing an additional 2,165 shares during the quarter. Patriot Financial Group Insurance Agency LLC’s holdings in CRISPR Therapeutics were worth $1,390,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in CRISPR Therapeutics by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 1,590,651 shares of the company’s stock worth $99,575,000 after acquiring an additional 51,926 shares during the last quarter. Wealthcare Advisory Partners LLC grew its holdings in CRISPR Therapeutics by 7.7% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 4,200 shares of the company’s stock valued at $286,000 after buying an additional 300 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in shares of CRISPR Therapeutics by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 16,876 shares of the company’s stock valued at $1,150,000 after acquiring an additional 411 shares during the last quarter. SteelPeak Wealth LLC grew its position in CRISPR Therapeutics by 129.4% in the first quarter. SteelPeak Wealth LLC now owns 10,253 shares of the company’s stock worth $699,000 after acquiring an additional 5,784 shares during the period. Finally, Mirador Capital Partners LP acquired a new position in shares of CRISPR Therapeutics in the 1st quarter worth approximately $203,000. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Up 2.5 %

CRSP stock traded up $1.20 during midday trading on Monday, reaching $48.56. The company had a trading volume of 865,172 shares, compared to its average volume of 1,443,059. The firm has a market capitalization of $4.12 billion, a PE ratio of -18.40 and a beta of 1.68. CRISPR Therapeutics AG has a fifty-two week low of $38.16 and a fifty-two week high of $91.10. The stock has a 50 day moving average price of $47.18 and a 200 day moving average price of $52.69.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The firm had revenue of $0.52 million during the quarter, compared to analyst estimates of $12.31 million. During the same period in the previous year, the company posted ($0.98) earnings per share. The firm’s quarterly revenue was down 99.3% on a year-over-year basis. Research analysts predict that CRISPR Therapeutics AG will post -5.6 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 4,293 shares of the business’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the transaction, the chief executive officer now directly owns 226,540 shares in the company, valued at $10,484,271.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the sale, the general counsel now owns 62,597 shares of the company’s stock, valued at $2,896,989.16. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Samarth Kulkarni sold 4,293 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the sale, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at $10,484,271.20. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 4.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Stifel Nicolaus decreased their target price on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating for the company in a report on Tuesday, August 6th. Barclays lowered their price objective on shares of CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 6th. Needham & Company LLC dropped their target price on CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research report on Friday, August 16th. Finally, Rodman & Renshaw assumed coverage on CRISPR Therapeutics in a research report on Friday, August 2nd. They issued a “buy” rating and a $90.00 price objective on the stock. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $75.19.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.